Compare ABVX & ONON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABVX | ONON |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | France | Switzerland |
| Employees | N/A | N/A |
| Industry | | Shoe Manufacturing |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 10.4B |
| IPO Year | 2022 | 2021 |
| Metric | ABVX | ONON |
|---|---|---|
| Price | $116.81 | $29.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 20 |
| Target Price | ★ $131.31 | $60.15 |
| AVG Volume (30 Days) | 844.2K | ★ 8.5M |
| Earning Date | 03-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $52.14 | $19.58 |
| Revenue Next Year | $4,132.27 | $19.98 |
| P/E Ratio | ★ N/A | $56.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.81 | $28.55 |
| 52 Week High | $148.83 | $51.08 |
| Indicator | ABVX | ONON |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 28.54 |
| Support Level | $107.67 | N/A |
| Resistance Level | $129.00 | $38.73 |
| Average True Range (ATR) | 3.58 | 1.08 |
| MACD | -0.85 | -0.44 |
| Stochastic Oscillator | 21.35 | 2.00 |
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Founded in Switzerland in 2010, sportswear firm On Holding generates more than 90% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of 2025 sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.